CSIMarket
 
Inari Medical Inc   (NARI)
Other Ticker:  
 
 
Price: $40.6500 $-0.08 -0.196%
Day's High: $40.79 Week Perf: -4.33 %
Day's Low: $ 39.90 30 Day Perf: -30.2 %
Volume (M): 1,109 52 Wk High: $ 71.85
Volume (M$): $ 45,073 52 Wk Avg: $60.57
Open: $40.72 52 Wk Low: $39.90



 Market Capitalization (Millions $) 2,217
 Shares Outstanding (Millions) 55
 Employees 450
 Revenues (TTM) (Millions $) 494
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 6

Inari Medical Inc
Inari Medical Inc. is a medical device company founded in 2013 and headquartered in Irvine, California. The company is dedicated to developing innovative technologies that improve the outcomes of patients with complex vascular disease. Inari Medical focuses on developing catheter-based intervention systems for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), which are the most common and serious forms of venous thromboembolism (VTE). The company's flagship product is the ClotTriever System, which is designed to remove large clot burdens from deep veins without the need for thrombolytic medication.

Inari Medical's ClotTriever System is a minimally invasive medical device that facilitates the rapid removal of large clots from deep veins in the legs. The device utilizes a vacuum-based system to physically remove the clot from the vein, which eliminates the need for thrombolytic drugs and reduces the risk of bleeding complications. The ClotTriever System is easy to use, and it can be performed in an outpatient setting with local anesthesia. This minimally invasive approach helps patients to recover more quickly and reduces the burden on hospitals.

Inari Medical has shown impressive growth in recent years, with the company's revenue increasing from $5 million in 2018 to $39 million in 2020. The company has attracted significant investment from venture capitalists, with two funding rounds raising a total of $234 million. In November 2020, Inari Medical completed an initial public offering (IPO) on the NASDAQ stock exchange, raising $156 million.

Inari Medical has also received regulatory approval from the U.S. Food and Drug Administration (FDA) for its ClotTriever System. The device was cleared for use in the United States in 2018, and further approvals have been granted in Europe, Japan, and other international markets. The company has also received several awards and recognitions for its innovation and impact on patient care.

Overall, Inari Medical is a rapidly growing medical device company that is dedicated to improving the outcomes of patients with complex vascular disease. With its innovative ClotTriever System, the company has demonstrated its ability to develop and market cutting-edge medical technologies that improve patient care, reduce healthcare costs, and enhance the quality of life for patients.


   Company Address: 6001 Oak Canyon Irvine 92618 CA
   Company Phone Number: 923-4747   Stock Exchange / Ticker: NASDAQ NARI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Inari Medical, a global leader in medical technology, recently announced the interim two-year results from its ClotTriever CLOUT Registry. The results revealed that the rates of Post Thrombotic Syndrome (PTS) observed at two years were not only excellent but also significantly lower when compared to rates reported in historical Deep Vein Thrombosis (DVT) trials.PTS is a potentially debilitatin...

Published Tue, Mar 12 2024 8:05 PM UTC

Inari Medical Announces Impressive Results from ClotTriever CLOUT Registry; Shows Significantly Lower Rates of Post Thrombotic Syndrome than Historical Deep Vein Thrombosis TrialsInari Medical, a global leader in medical technology, recently announced the interim two-year results from its ClotTriever CLOUT Registry. The results revealed that the rates of Post Thrombotic Synd...

Inari Medical Inc

Inari Medical Inc. Celebrates Record Revenue Surge in Fourth Quarter of 2023 Earnings Season

Inari Medical Inc, a leading medical device company, recently announced a significant surge in revenue for the fourth quarter of 2023. Despite reporting a net loss of $-0.08 per share, the company's revenue increased by an impressive 22.949% to $132.50 million compared to the same period the year before. This revenue surge outperformed the average top-line elevation of 7.86% seen in the Medical Equipment & Supplies sector.
Although the company experienced a decrease in earnings per share compared to the previous quarter, with EPS falling to $-0.03 from $-0.55 in the prior fiscal year, their revenue continued to improve. Inari Medical reported a net loss of $-4.665 million in the fourth quarter of 2023, a significant improvement from the deficit of $-5.798 million in the same period the year before. The company also reported revenue of $493.56 million for the fiscal 12 months of 2023, representing a 28.71% increase from the previous year.

Clinical Study

Inari Medical Initiates Groundbreaking Clinical Study to Advance Treatment Guidelines for Pulmonary Embolism Patients Globally

Published Mon, Nov 27 2023 9:20 PM UTC



Inari Medical Inc, a leading innovator in the field of medical devices, recently announced the enrollment of the first patient in its groundbreaking PEERLESS II Randomized Controlled Trial (RCT). This extensive clinical study aims to revolutionize the treatment guidelines for intermediate-risk Pulmonary Embolism (PE) patients on a global scale. The trial will rando...

Inari Medical Inc

Examining the Concerning Factors and Potential Risks behind Inari Medical Inc's Positive Financial Results



Inari Medical Inc, a prominent player in the Medical Equipment & Supplies industry, recently reported positive financial results for its most recent fiscal period. While these results may appear encouraging at first glance, a closer examination reveals concerning indicators and potential risks for the company. This article aims to present a bearish perspective on Inari Medical Inc based on several key factors.
1. Stagnating Business Growth
While Inari Medical Inc has showcased positive growth in profits, it is essential to consider the broader industry context. In the third quarter of 2023, when compared to the same quarter the previous year, the overall Medical Equipment & Supplies industry experienced an average business growth of 0.80%. Inari Medical Inc's higher growth rate of 25% may indicate some relative success, but further analysis shows that it falls short in absolute terms when compared to industry peers.

Inari Medical Inc

Inari Medical Inc Announces Impressive Surge in Q2 2023 Revenues, Turning Profitable with 28.316% Growth



Inari Medical Inc, a leading player in the Medical Equipment & Supplies industry, has recently reported impressive financial results for the second quarter of 2023. The company's revenue surged by an astonishing 28.316% to reach $119.01 million, marking a significant turnaround for the company as it shifted from losses to profitability. This remarkable achievement can be attributed to various factors, including increased demand and a positive shift in earnings per share (EPS).
Revenue Growth:
During the second quarter of 2023, Inari Medical outperformed its industry peers, recording a 28.316% revenue growth. In comparison, the average revenue growth for the Medical Equipment & Supplies industry was just 0.99%. This excellent performance demonstrates the company's ability to capitalize on market opportunities and gain a competitive edge.






 

Inari Medical Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Inari Medical Inc does not provide revenue guidance.

Earnings Outlook
Inari Medical Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com